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Abstract
Background: Syk (Splenic Tyrosine Kinase) is an intracellular receptor protein kinase involved in
cell proliferation, differentiation and phagocytosis. It has been studied in T and B lymphocytes, NK
cells and platelets. The strong expression of Syk in mammary gland prompted research into its
potential role in mammary carcinogenesis. There have been very few studies about its role in breast
cancer with conflicting results. This study aims to investigate the hypothesis that Syk expression is
down-regulated in breast cancer compared with ANCT and the association between its expression
and clinicopathological parameters.
Materials and methods: mRNA was extracted from 48 breast cancer specimens. Relative Syk
to ribosomal RNA expression was determined by RT-PCR and Taqman methodology. Mann-
Whitney U test was used to examine the association between Syk expression in cancer and ANCT.
Spearman's rank correlation test was used to examine the association between Syk expression in
tumours and patients' age, tumour size, tumour grade, estrogen and progesterone receptor status,
lymph node metastasis, vascular invasion and clinical outcome.
Results: The median for the relative value of Syk expression was 0.17 and 0.18 (range: 0.12 – 0.56
and 0.0 – 1.77) for tumours and ANCT respectively. There was no significant association between
Syk expression in cancers and ANCT (p= 0.598) nor between Syk expression in tumours and
patients' age, tumour size, tumour grade, estrogen and progesterone receptor status, lymph node
metastasis, vascular invasion or prognosis.
Conclusion: This study shows that Syk mRNA expression does not seem to vary between breast
tumours and ANCT. Furthermore, we observed no significant association between Syk expression
and clinicopathological parameters.
Introduction
Breast cancer development and progression are thought to
occur through a multistep process, including oncogene
activation and mutation or loss of tumour suppresser
genes [1]. Protein-tyrosine kinases (PTKs) have been clas-
sified into two families: trans-membrane receptors family
and non- receptor family [2-5]. More than 30 receptor
type PTKs have been identified in mammals and divided
into 11 subfamiliies [6], of which we mention Tec, JAK,
Sck, Fes, Abl, Fak, Scr and Syk [6,7]. Syk PTKs family com-
prises Syk and ZAP-70 [6]. Syk (named after Spleen Tyro-
sine Kinase) is associated with cell surface receptors to
amplify receptor-activated signals inside the cells [6]. Syk
family contains tandem Scr homology 2 (SH2) and c-ter-
minal kinase domains interrupted by two interdomains A
and B [8-12]. Syk assembles into signalling complexes at
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the plasma membrane via interaction between its tandem
SH2 domains and a tyrosine-phosphorylated immunore-
ceptor tyrosine-based activation motif (ITAM), and this
binding activates Syk [6,11,13,14] which is then tyrosine
phosphorylated by autophosphorylation [5,6]. ITAM
becomes phosphorylated on both tyrosine residues creat-
ing high affinity binding sites for the tandem SH2
domains [15]. Receptors containing these ITAMs act to
initiate an activation cascade [16]. For example, stimula-
tion of the B cell receptors (BCR) initiates a biochemical
cascade, in which PTKs activation is the earliest known
event [16]. Thus, Syk is recruited, activated by binding of
SH2 to ITAM and then subsequently phosphorylated by
autophosphorylation. Activated Syk phosphorylates its
own substrate, which mediates further functions in the
cells [16]. Syk is involved in mediating diverse cellular
responses such as proliferation, differentiation and
phagocytosis [12,17,18]. This includes T cell receptor
(TCR) function and thymocyte development [7,12], B cell
antigen receptor signalling [19] and natural killer (NK)
cell differentiation (although not essential) and platelet
activation by collagen [13]. Syk is not tyrosine phosphor-
ylated in resting cells, possibly because it is dephosphor-
ylated by specific protein tyrosine phosphatases [6].
Syk expression was found in a variety of organs such as
spleen, heart, mammary gland [20] and in hepatocytes
[21], haemtopoietic cells [22] and colonic carcinoma cells
[23]. In an article published in Nature, Coopman et al
[18] have reported that Syk was commonly expressed in
normal human breast tissue, benign breast lesions and
low-tumorigenic breast cancer cell lines whereas Syk
mRNA and protein were low or undetectable in invasive
breast carcinoma tissue and cell lines. In contrast with
that, Fluck et al [20] demonstrated that aggressive metas-
tasising mammary gland tumours expressed higher level
of Syk compared with well differentiated non-metastasis-
ing tumours in a murine model of breast cancer. More
recently, Yuan and colleagues [24] demonstrated that Syk
was frequently inactivated through an epigenetic pathway
in breast cancer. Using breast cancer cell lines, and human
breast cancer tissues and PCR methodology, the authors
observed that Syk was hypermethylated and therefore
inactive in 12 (32%) of 37 breast tumours whereas all of
the matched neighbouring normal breast tissue exhibited
unmethylated DNA status (i.e. active Syk). Such observa-
tions are consistent with the hypothesis that Syk functions
as a tumour suppresser gene and DNA methylation of this
gene seems to play an important role in mammary car-
cinogenesis [25,26]. Other authors [22,27] have demon-
strated that Syk is a prognostic factor in breast cancer.
However, Wang et al, using immunoblotting technique,
have found that breast cancer tissues expressed variable
levels of Syk compared with normal breast tissues [5].
The present study aims to determine Syk mRNA expres-
sion in both breast cancer and adjacent normal breast tis-
sue (ANCT) using RT-PCR methodology and correlate the
expression in cancer with patients' age, tumour size,
tumour grade, estrogen and progesterone receptor status,
lymph node metastasis, vascular invasion and clinical
outcome.
Materials and methods
Institutional guidelines including ethical approval and
informed consent were followed. Patients were treated
with wide local excision or mastectomy and axillary node
dissection. Patients with estrogen and /or progesterone
positive tumours received tamoxifen. Adjuvant radiother-
apy was administered to all patients who had breast con-
serving surgery and to patients undergoing mastectomy
for node positive disease. Chemotherapy was given to fit
patients (<65 years) with lymph node involvement or
high grade tumours.
A 50 mg tumour specimen and an other 50 mg of macro-
scopically normal adjacent normal breast tissue (ANCT)
were obtained from each patient. They were frozen in liq-
uid nitrogen within 30 minutes of excision and stored at -
70°C until use.
RNA extraction
mRNA was extracted from 25 tumours and matching 23
ANCT using Absolutely RNA, RT-PCR Miniprep (Strata-
gene) Kit according to the manufacturer's protocol. Extrac-
tion of RNA was carried out in a laboratory separate to
that used for RT-PCR.
RT Step
cDNA was synthesised. Conditions for reverse tran-
scriptase were 25°C for 10 minutes, 48°C for 30 minutes
and 95°C for 5 minutes. Genomic contamination was
tested for and was virtually nil.
PCR
Taqman RT-PCR was performed for each sample using
ABI PRISM 7700 Sensor Detection System (Applied Bio-
systems). The primers were designed using the Primer
Selection Software. The primers used were ATT AGC AGA
AGC AAA TGT CAT GCA (forward) and CCT CGC ATA
TCC CGA TCA TC (reverse). PCR was carried out for 40
cycles of 15 seconds at 95°C and 1 minute at 60°C.
The relative expression of Syk to that of ribosomal RNA
was determined using the Sequence Detection System
Software. This experiment was carried out three times and
the average values were calculated and used for statistical
analysis. The positive and negative controls were ribos-
omal RNA and sterile water respectively.Journal of Carcinogenesis 2005, 4:7 http://www.carcinogenesis.com/content/4/1/7
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Statistical analysis
Mann-Whitney U test was used to examine the association
between Syk expression in cancer and ANCT. Spearman's
rank correlation test was used to examine the association
between Syk expression in tumours and patients' age,
tumour size, tumour grade, estrogen and progesterone
receptor status, lymph node metastasis, vascular invasion
and clinical outcome.
Results
25 breast tumours and matching 23 ANCT were included
in this study with patients age range 25–75 years (median
56.5, mean 56.80).
Syk expression in tumours and ANCT
The median for the relative value of Syk expression was
0.17 and 0.18 (range: 0.12 – 0.56 and 0.0 – 1.77) for
tumours and ANCT respectively. Mann-Whitney U test
showed no significant association between Syk expression
in cancers and ANCT (p= 0.598). (Figures 1 and 2)
Correlation between Syk expression in tumours and 
clinicopathological parameters
The expression of Syk in tumours was correlated with
patients' age, tumour size, tumour grade (well, moder-
ately or poorly differntiated), estrogen and progesterone
receptor status (positive, weak positive or negative),
Scatter plot to show the relationship between Syk expression in cancers and normal breast tissues Figure 1
Scatter plot to show the relationship between Syk expression in cancers and normal breast tissues.
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lymph node metastasis, vascular invasion, recurrence and
clinical outcome (distant metastasis and death with a
median follow up of 1.95 years). Spearman's rank correla-
tion test showed no significant association between Syk
expression in tumours and patients' age, tumour size,
tumour grade, estrogen and progesterone receptor status,
lymph node metastasis, vascular invasion or prognosis
survival curves. Table 1 demonstrates the correlation coef-
ficient and p values for the variables studied.
Box plot to show the relationship between Syk expression in cancers and normal breast tissues Figure 2
Box plot to show the relationship between Syk expression in cancers and normal breast tissues.
Table 1: the correlation coefficient and p values for the variables studied.
Age Size Hist Grade LN Vasc ER PR Rec OC
Corr coef -0.104 0.102 0.01 0.137 -0.007 0.141 0.089 -0.294 0.130 0.339
P value 0.653 0.679 0.963 0.626 0.977 0.603 0.708 0.208 0.595 0.143
TUMOUR
2.2 2.0 1.8 1.6 1.4 1.2 1.0 .8
S
Y
K
2.0
1.5
1.0
.5
0.0
-.5Journal of Carcinogenesis 2005, 4:7 http://www.carcinogenesis.com/content/4/1/7
Page 5 of 6
(page number not for citation purposes)
Discussion
Our report in the present article represents the largest
study of Syk expression in human breast cancer and
ANCT. It has that Syk mRNA is expressed in both human
breast cancer and ANCT specimens. This observation is
consistent with the established role of Syk in the control
of cell proliferation and intracellular signalling in epithe-
lial cells and immunocytes [12,17,18]. The lack of statisti-
cally significant difference between Syk mRNA expression
in the whole tumour and ANCT specimens observed in
this study may represent a true observation and therefore,
Syk should not be considered a tumour suppressor gene.
It does not, however, exclude the presence of different lev-
els of Syk expression in malignant and benign mammary
epithelial cells. Breast tumours are heterogenous lesions
[5] that contain various components including fibroblasts
and lymphocytes. The latter can make up to 45% of the
whole breast tumour volume [28]. Lymphocytes are
known to express significant levels of Syk and this could
lead to a false overestimation of Syk mRNA in epithelial
cancer cells. A more accurate estimation of Syk mRNA in
epithelial elements can be achieved by using Laser capture
microdissection (LCM) in order to separate epithelial cells
from other components in both tumours and ANCT.
Alternatively, in situ hybridization and immunohisto-
chemistry techniques can be used to identify the cellular
source of the enzyme (Coopman et al). The ANCT in our
study was obtained from macroscopically normal breast
tissue more than 10 mm away from the primary tumour.
However, one cannot exclude the presence of malignant
epithelial cells in these specimens, as histopathological
verification of ANCT was not carried out. Another limita-
tion of the present study is the fact that we measured
mRNA transcript rather than the protein, which is the
effective end product of the gene. However, experimental
data from breast cancer cell lines suggest that there is a
good correlation between mRNA and protein expression
(Coopman et al). Furthermore, the presence of splice var-
iants of Syk mRNA (Fluck et al) represents another limita-
tion to our RT-PCR methodology. Our results also show
that Syk mRNA expression in breast tumours as deter-
mined by RT-PCR methodology is independent of tumour
stage and therefore it is unlikely to play a prognostic role
in patients with breast cancer.
Abbreviations
Corr Coef: Correlation coefficient
Hist: Histology
LN: Lymph node metastasis
Vasc: Vascular invasion
ER: Estrogen receptors
PR: Progesterone receptors
Rec: Recurrence
OC: Clinical outcome
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